EA
AMRI

Emerald Advisers’s Albany Molecular Research Inc AMRI Stock Holding History

Emerald Advisers’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-669,705
Closed -$9.4M – 254
2017
Q1 		$9.4M Sell
669,705
-23,850
-3% -$391K 0.39% 96
2016
Q4 		$13M Buy
693,555
+279,877
+68% +$4.76M 0.55% 73
2016
Q3 		$6.83M Buy
+413,678
New +$6.13M 0.3% 116

Other funds holding AMRI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $121M AUM 74.36% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Emerald Advisers's AMRI Position: Q2 2017 in Review

Emerald Advisers sold out of Albany Molecular Research Inc (AMRI) in Q2 2017, closing a stake of 669,705 shares — an estimated $9.4M sold.

Emerald Advisers first reported a position in AMRI in Q3 2016 and held it in 3 quarters. The position peaked at $13M in Q4 2016. 136 funds tracked by Wall St. Rank hold AMRI as of Q2 2017.

  • Emerald Advisers reported no remaining Albany Molecular Research Inc position as of Q2 2017 after selling out during the quarter.
  • Emerald Advisers sold 669,705 Albany Molecular Research Inc shares in Q2 2017, an estimated $9.4M.
  • Emerald Advisers first reported a position in Albany Molecular Research Inc in Q3 2016 and held it in 3 quarters.
  • Emerald Advisers's Albany Molecular Research Inc position peaked at $13M in Q4 2016.
  • 136 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2017.

Based on Emerald Advisers's 13F filing for Q2 2017, filed 28 Jul 2017.